Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help
Stockholders requested to vote FOR Proposal SAN DIEGO , July 16, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer,
Data for the detection and monitoring of key predictive biomarkers for patients with newly diagnosed or progressing metastatic lung cancer on therapy to be presented at the Association for Molecular Pathology Annual Meeting SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc.
Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team SAN DIEGO / — Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept’s Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr.
MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients with HER2- Tumors by Tissue Analysis San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) and
Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which
SAN DIEGO , March 9, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’
SAN DIEGO , March 10, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that Progenetics LTD will market and distribute Biocept's complete portfolio of
